{"disease":{"id":"her2-positive-gastric-cancer","name":"her2 positive gastric cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06764875","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06532006","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT07332533","title":"A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":490,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT06123494","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06846996","title":"Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China","phase":"","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05993234","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","phase":"","overall_status":"RECRUITING","enrollment_count":257,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT04650451","title":"Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":220,"lead_sponsor_name":"Bellicum Pharmaceuticals","has_results":false},{"nct_id":"NCT06998771","title":"JSKN003 Combined Treatment of HER2-positive Gastric Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT06730373","title":"First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT04520295","title":"ctDNA Screening in Advanced HER2 Positive Gastric Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05348161","title":"Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT03409848","title":"Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT03330561","title":"PRS-343 in HER2-Positive Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Pieris Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04082364","title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT05190445","title":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Pieris Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05619016","title":"[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT04920747","title":"Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT01602406","title":"Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05411432","title":"Clinical Study of 68Ga Labeled HER2 Affibody Analogues","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":56,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05586061","title":"First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT05640830","title":"Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Kangbuk Samsung Hospital","has_results":false},{"nct_id":"NCT06253650","title":"Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Gruppo Oncologico del Nord-Ovest","has_results":false},{"nct_id":"NCT07334431","title":"Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03319459","title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT07126561","title":"Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":43,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT06439550","title":"Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT06414733","title":"HER-2 B Cell Peptide Vaccine","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Pravin T.P Kaumaya","has_results":false},{"nct_id":"NCT03650348","title":"PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Pieris Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05311189","title":"Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05313906","title":"RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06572319","title":"Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05070598","title":"Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT02015169","title":"Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05715931","title":"Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Yu jiren","has_results":false},{"nct_id":"NCT05165602","title":"Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT04727151","title":"TAC T-cells for the Treatment of HER2-positive Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Triumvira Immunologics, Inc.","has_results":true},{"nct_id":"NCT06492317","title":"RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT05555251","title":"BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT06023758","title":"Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT04467515","title":"A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Precirix","has_results":true},{"nct_id":"NCT04319757","title":"ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Acepodia Biotech, Inc.","has_results":false},{"nct_id":"NCT05955833","title":"89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":6,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT05091528","title":"A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Silverback Therapeutics","has_results":true},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}